Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
24 hedge funds and large institutions have $4.71M invested in Aptose Biosciences, Inc. in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 23 closing their positions.
45% less funds holding
Funds holding: 44 → 24 (-20)
65% less capital invested
Capital invested by funds: $13.5M → $4.71M (-$8.8M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
87% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.17K |
| 2 |
Morgan Stanley
New York
|
+$1.24K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$621 |
| 4 |
CSC
Caldwell Sutter Capital
Sausalito,
California
|
+$621 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$207 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.28M |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$925K |
| 3 |
Renaissance Technologies
New York
|
-$205K |
| 4 |
VC
Voss Capital
Houston,
Texas
|
-$152K |
| 5 |
Goldman Sachs
New York
|
-$60.2K |
APTO Hedge Fund Activity: Q2 2023 in Review
24 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2023, worth a combined $4.71M — down 65% from $13.5M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of APTO and 3 opened new positions — a net loss of 20 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was Royal Bank of Canada, adding an estimated $5.17K. The largest seller was Nantahala Capital Management, cutting an estimated $1.28M.
- 24 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2023, down from 44 in Q1 2023.
- Funds reported $4.71M of Aptose Biosciences, Inc. stock for Q2 2023, down 65% quarter-over-quarter.
- 3 funds opened new Aptose Biosciences, Inc. positions in Q2 2023 and 23 closed out, a net change of -20 holders.
- The largest Aptose Biosciences, Inc. buyer in Q2 2023 was Royal Bank of Canada, an estimated $5.17K added.
- The largest Aptose Biosciences, Inc. seller in Q2 2023 was Nantahala Capital Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q2 2023.